Who Replaced Peptide Sciences? The Best Alternatives in 2025

Why Peptide Sciences Was Hard to Replace

Most peptide suppliers come and go. Peptide Sciences stayed — and that consistency was a meaningful differentiator. Over more than ten years of operation, they built a catalog that covered nearly every major research peptide category: healing and recovery peptides like BPC-157 and TB-500, GH secretagogues like CJC-1295 and Ipamorelin, nootropics, GLP-1 compounds, and longevity peptides. For researchers who had tested and validated their products, switching was not a trivial decision.

Their Certificate of Analysis (CoA) documentation became a baseline expectation. Customers knew what they were getting, batch to batch, and could verify it. That kind of documented quality consistency is rare in a market where many suppliers publish minimal product information.

The company's shutdown — driven by the same FDA enforcement wave that has shut down dozens of US-based research peptide suppliers since 2023 — left a gap that not every supplier can fill. Finding a genuine replacement means finding a company that matches on catalog depth, quality documentation, and community trust. That combination is uncommon.

What a Real Replacement Needs to Offer

Switching suppliers is not just about finding someone who sells BPC-157. A genuine replacement for Peptide Sciences needs to meet a higher bar across several dimensions. Here is what matters most.

The Current Research Peptide Market

The US-based research peptide market has consolidated significantly since 2023. The FDA's enforcement actions, combined with payment processor pressure and banking restrictions, have shuttered many of the mid-tier suppliers that once offered competition. What remains is a smaller number of suppliers — some operating domestically, others shipping internationally — with widely varying quality standards.

International suppliers, particularly those based in Europe and Australia, have become increasingly prominent as US-based options have dwindled. Some of these suppliers have strong quality controls and third-party testing programs. Others operate with minimal documentation and inconsistent sourcing. Shipping times and customs considerations are additional variables researchers must weigh.

The most important factor in this market is not price — it is verifiable quality. An underdosed or contaminated peptide is worse than no peptide at all, and the cost of low-quality sourcing in a research context is measured in wasted time and compromised data, not just wasted money.

One area where Peptide Sciences was increasingly recognized — and where their absence is especially felt — is in the availability of pre-formulated combination peptide blends. Individual peptides have well-documented research profiles, but many researchers work with synergistic stacks where two compounds are co-administered for complementary mechanisms.

Not every supplier stocks these combinations. The ability to source pre-blended formulations simplifies research protocols and ensures consistent ratios. Here are several of the most widely studied combination formulations:

Availability of these formulations varies significantly by supplier. Researchers who rely on combination protocols should confirm stock and batch documentation before committing to a source.

After evaluating the current market, Base Peptides is our top recommended replacement for Peptide Sciences. The primary reason: product selection.

As with any supplier in this space, we recommend reviewing the available batch documentation and Certificates of Analysis before purchasing. Product selection and quality documentation together are the two most important criteria — and Base Peptides performs strongly on both.